IKEUCHI
8.1.2024 13:01:28 CET | Business Wire | Press release
H. IKEUCHI & CO., LTD., a Japanese spray nozzles manufacturer, has launched a global campaign to introduce humidity control systems powered by “Dry Fog” technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108276401/en/
Each individual photo available upon request: IKEUCHI offers humidity control systems using Dry Fog not only preventing static electricity in SMT processes but also significantly slashing operating costs and CO2 emissions.(Photo: Business Wire)
“Dry Fog” is formed out of ultrafine water droplets, each measuring 10 μm or less in diameter, generated by specialized spray nozzles. This fog rapidly evaporates into the air without wetting the objects it touches.
In the realm of surface-mount technology (SMT) processes, effective humidity control is crucial to combat electrostatic discharge (ESD) issues and challenges arising from static electricity and dry air. IKEUCHI's Dry Fog Humidification System emerges as a groundbreaking solution, delivering seven key benefits.
1. ESD Damage Prevention
As electronic components shrink, susceptibility to electrostatic discharge increases. The Dry Fog system ensures a uniform humidity level, preventing the risk of ESD damage.
2. Reduced Pick-and-Place Errors
Maintaining optimal humidity levels minimizes errors in the pick-and-place process caused by components sticking to or popping out from the tape due to static charge, boosting productivity.
3. Consistent Solder Print Quality
Humidity control during solder printing prevents issues like rapid drying or excessive moisture absorption, ensuring consistent solder print quality and product reliability.
4. Airborne Particle Reduction
Humidification curbs airborne particles, reducing defects caused by particle adherence. The Dry Fog system significantly decreases airborne particles with increased humidity.
5. Significant Operating Cost Reduction
Compared to conventional steam humidification, the Dry Fog system slashes operating costs by 68%, resulting in $50,000/year savings and a 70% CO2 emissions reduction.
6. Cooling Cost Reduction
Evaporative cooling of the Dry Fog lowers ambient temperatures, yielding an $18,000/year saving in cooling expenses at an SMT facility.
7. Healthier Work Environment
Beyond manufacturing, the Dry Fog system reduces sick leave by maintaining a relative humidity of 50% or above, leading to fewer sick days during winter.
In conclusion, IKEUCHI's Dry Fog Humidification System is a comprehensive solution addressing crucial aspects of SMT processes, enhancing productivity, reducing costs, and fostering a healthier workplace. This technology offers a transformative approach to humidity control in electronics manufacturing.
Links to Articles: Part 1, Part 2, Part. 3
Network: U.S., Europe, China, Taiwan, Indonesia, Thailand, Japan
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108276401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release
Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
